Isthmus Partners LLC Buys 450 Shares of Haemonetics Co. (NYSE:HAE)

Isthmus Partners LLC increased its stake in Haemonetics Co. (NYSE:HAE) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,220 shares of the medical instruments supplier’s stock after acquiring an additional 450 shares during the quarter. Isthmus Partners LLC owned about 0.08% of Haemonetics worth $3,140,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares during the last quarter. Wellington Management Group LLP grew its stake in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after purchasing an additional 363,702 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 29.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock valued at $88,433,000 after acquiring an additional 250,833 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Haemonetics during the 4th quarter valued at $19,002,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Haemonetics by 439.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock worth $17,720,000 after acquiring an additional 179,621 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on HAE shares. Needham & Company LLC decreased their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Finally, Raymond James reiterated a “strong-buy” rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Stock Up 2.2 %

Haemonetics stock opened at $68.70 on Monday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a market cap of $3.45 billion, a PE ratio of 27.05, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The firm’s 50-day simple moving average is $69.77 and its 200 day simple moving average is $75.74.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Research analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.